GMED Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 4.03% compared to Globus Medical's net margin of 14.45%. Globus Medical's return on equity of 2.56% beat Boston Scientific's return on equity of 8.96%.

Globus Medical has a consensus price target of $97.46, signalling upside risk potential of 33.38%. On the other hand Boston Scientific has an analysts' consensus of $116.84 which suggests that it could grow by 15.52%. Given that Globus Medical has higher upside potential than Boston Scientific, analysts believe Globus Medical is more attractive than Boston Scientific.

Globus Medical has a beta of 1.284, which suggesting that the stock is 28.425% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $657.3M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Globus Medical's net income of $26.5M is lower than Boston Scientific's net income of $674M. Notably, Globus Medical's price-to-earnings ratio is 97.43x while Boston Scientific's PE ratio is 73.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.99x versus 8.58x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of 4.03% compared to Globus Medical's net margin of 7.28%. Globus Medical's return on equity of 2.56% beat Integer Holdings's return on equity of 7.65%.

Globus Medical has a consensus price target of $97.46, signalling upside risk potential of 33.38%. On the other hand Integer Holdings has an analysts' consensus of $148.25 which suggests that it could grow by 22.06%. Given that Globus Medical has higher upside potential than Integer Holdings, analysts believe Globus Medical is more attractive than Integer Holdings.

Globus Medical has a beta of 1.284, which suggesting that the stock is 28.425% more volatile than S&P 500. In comparison Integer Holdings has a beta of 1.086, suggesting its more volatile than the S&P 500 by 8.599%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $657.3M, which are larger than Integer Holdings quarterly revenues of $449.5M. Globus Medical's net income of $26.5M is lower than Integer Holdings's net income of $32.7M. Notably, Globus Medical's price-to-earnings ratio is 97.43x while Integer Holdings's PE ratio is 36.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.99x versus 2.50x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 4.03% compared to Globus Medical's net margin of -58.2%. Globus Medical's return on equity of 2.56% beat Masimo's return on equity of -23.05%.

Globus Medical has a consensus price target of $97.46, signalling upside risk potential of 33.38%. On the other hand Masimo has an analysts' consensus of $195.70 which suggests that it could grow by 20.33%. Given that Globus Medical has higher upside potential than Masimo, analysts believe Globus Medical is more attractive than Masimo.

Globus Medical has a beta of 1.284, which suggesting that the stock is 28.425% more volatile than S&P 500. In comparison Masimo has a beta of 1.278, suggesting its more volatile than the S&P 500 by 27.807%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $657.3M, which are larger than Masimo quarterly revenues of $600.7M. Globus Medical's net income of $26.5M is higher than Masimo's net income of -$349.6M. Notably, Globus Medical's price-to-earnings ratio is 97.43x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.99x versus 4.20x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 4.03% compared to Globus Medical's net margin of 28.26%. Globus Medical's return on equity of 2.56% beat ResMed's return on equity of 25.76%.

Globus Medical has a consensus price target of $97.46, signalling upside risk potential of 33.38%. On the other hand ResMed has an analysts' consensus of $264.15 which suggests that it could grow by 11.88%. Given that Globus Medical has higher upside potential than ResMed, analysts believe Globus Medical is more attractive than ResMed.

Globus Medical has a beta of 1.284, which suggesting that the stock is 28.425% more volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.88% to investors and pays a quarterly dividend of $0.53 per share. Globus Medical pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Globus Medical quarterly revenues are $657.3M, which are smaller than ResMed quarterly revenues of $1.3B. Globus Medical's net income of $26.5M is lower than ResMed's net income of $365M. Notably, Globus Medical's price-to-earnings ratio is 97.43x while ResMed's PE ratio is 26.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.99x versus 6.93x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.